D.E. Shaw & Co’s NovoCure NVCR Stock Holding History

D.E. Shaw & Co’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-15,200	Closed	-$196K	–	4877
2025 Q3	$196K	Buy	+15,200	New	+$203K	﹤0.01%	4289
2025 Q1	–	Sell	-66,700	Closed	-$1.99M	–	4589
2024 Q4	$1.99M	Hold	66,700	–	–	﹤0.01%	2740
2024 Q3	$1.04M	Hold	66,700	–	–	﹤0.01%	3245
2024 Q2	$1.14M	Buy	66,700 +25,400	+62%	+$447K	﹤0.01%	3097
2024 Q1	$646K	Buy	+41,300	New	+$607K	﹤0.01%	3359
2022 Q2	–	Sell	-10,000	Closed	-$829K	–	5631
2022 Q1	$829K	Sell	10,000 -30,000	-75%	-$2.21M	﹤0.01%	4052
2021 Q4	$3M	Hold	40,000	–	–	﹤0.01%	2954
2021 Q3	$4.65M	Buy	40,000 +10,000	+33%	+$1.51M	﹤0.01%	2167
2021 Q2	$6.66M	Buy	30,000 +20,000	+200%	+$3.89M	0.01%	1813
2021 Q1	$1.32M	Sell	10,000 -9,500	-49%	-$1.5M	﹤0.01%	2900
2020 Q4	$3.37M	Buy	+19,500	New	+$2.67M	﹤0.01%	2177
2020 Q3	–	Sell	-19,100	Closed	-$1.13M	–	4052
2020 Q2	$1.13M	Sell	19,100 -10,900	-36%	-$717K	﹤0.01%	2834
2020 Q1	$2.02M	Buy	30,000 +12,600	+72%	+$996K	﹤0.01%	2154
2019 Q4	$1.47M	Hold	17,400	–	–	﹤0.01%	2718
2019 Q3	$1.3M	Buy	+17,400	New	+$1.39M	﹤0.01%	2669
2019 Q2	–	Sell	-20,000	Closed	-$963K	–	3800
2019 Q1	$963K	Buy	+20,000	New	+$963K	﹤0.01%	2629

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

D.E. Shaw & Co's NVCR Position: Q2 2026 in Review

D.E. Shaw & Co increased its NovoCure (NVCR) stake by 58% in Q2 2026, buying an estimated $5.68M and bringing the position to 1,022,480 shares worth $15.5M. The position accounts for 0.01% of the portfolio, ranked #1482.

D.E. Shaw & Co first reported a position in NVCR in Q4 2016 and has held it in 33 quarters since. The position peaked at $34.6M in Q2 2019. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

D.E. Shaw & Co held 1,022,480 shares of NovoCure worth $15.5M as of Q2 2026.
D.E. Shaw & Co bought 375,418 NovoCure shares in Q2 2026, an estimated $5.68M.
NovoCure made up 0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #1482 holding.
D.E. Shaw & Co first reported a position in NovoCure in Q4 2016 and has held it in 33 quarters since.
D.E. Shaw & Co's NovoCure position peaked at $34.6M in Q2 2019.
218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.